At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 277 enrolled
Drug / intervention
Rucaparibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
In Brief
A Phase 2 clinical trial evaluating Rucaparib for Metastatic Castration Resistant Prostate Cancer. Completed, enrolled 277 participants across 149 sites in 12 countries.
Detailed Summary
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Canada, Denmark, France, Germany, Ireland, Israel, Italy, Spain, United Kingdom, United States
CollaboratorsFoundation Medicine
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartFeb 2017
Primary CompletionJul 2021
Study CompletionJul 2021
TodayJul 2026
First PostedNov 2, 2016
Enrollment StartFeb 15, 2017
Primary CompletionJul 18, 2021
Study CompletionJul 27, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.7 years ago
Interventions
Rucaparibdrug
Rucaparib will be administered daily